BioRegenx, Inc.
BRGX
$0.01
-$0.0039-28.06%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -13.41% | 11.86% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -13.41% | 11.86% | |||
| Cost of Revenue | -14.30% | -20.83% | |||
| Gross Profit | -13.18% | 25.81% | |||
| SG&A Expenses | -23.20% | -67.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -21.84% | -72.40% | |||
| Operating Income | 44.29% | 90.85% | |||
| Income Before Tax | 33.20% | 98.55% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 33.20% | 98.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 33.20% | 98.55% | |||
| EBIT | 44.29% | 90.85% | |||
| EBITDA | 61.21% | 88.22% | |||
| EPS Basic | 33.33% | 98.41% | |||
| Normalized Basic EPS | 50.00% | 85.71% | |||
| EPS Diluted | 33.33% | 98.41% | |||
| Normalized Diluted EPS | 50.00% | 85.71% | |||
| Average Basic Shares Outstanding | 0.23% | -1.51% | |||
| Average Diluted Shares Outstanding | 0.23% | -1.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||